Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing
Sagar
R. Shah1,2, Alfredo Quinones-Hinojosa1, Shuli Xia3,4*
1Department of Neurologic Surgery, Mayo Clinic, Jacksonville, FL, USA
2Department of Biomedical Engineering, Johns
Hopkins School of Medicine, Baltimore, MD, USA
3 Hugo W. Moser Research Institute at Kennedy
Krieger, Baltimore, MD, USA
4 Department of Neurology, Johns Hopkins School
of Medicine, Baltimore, MD, USA
*Corresponding
author:
Shuli Xia, Hugo W. Moser
Research Institute at Kennedy Krieger, Department of Neurology, Johns
Hopkins School of Medicine, Baltimore,
MD, 21205, USA. Tel: +14439239498; Email: xia@kennedykrieger.org
Received Date: 20 September,
2018; Accepted Date: 26 September,
2018; Published Date: 03 October,
2018
Citation: Shah SR, Quinones-Hinojosa A, Xia S (2018) Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing. J Oncol Res Ther: JONT-166. DOI: 10.29011/2574-710X. 000066
1. Abstract
Mutations in the Isocitrate Dehydrogenase 1 (IDH1) gene occur in 70% of grade II and grade III gliomas, 10% of acute myeloid leukemia, as well as cholangiocarcinomas, melanomas, and chondrosarcomas. Numerous mechanisms have been proposed to illustrate the biological function of mutant IDH1. Most functional studies of mutant IDH1 have been conducted in exogenous overexpression systems with the IDH1 wild type background. This mini-review comments on recent publication by Wei et al, in which a highly efficient “single base editing” approach was employed to generate monoallelic IDH1 R132H mutation without the induction of a double strand break in the IDH1 gene.
2. Keywords: Glioma; Heterozygous IDH1 R132H Mutation; Single Base Editing; Yes-Associated Protein (YAP)
3.
Introduction
Gliomas
are the most prevalent type of tumors of the central nervous systems,
accounting for up to 30% of all primary lesions and nearly 80% of all malignant
forms [1,2]. Given their anatomical localization
and locally infiltrative nature, these tumors are associated with high
morbidity and mortality. Despite radical surgical resection coupled with chemo-
and radiotherapy, these tumors often recur, leading to a dismal overall
prognosis. With an approximate incident rate of 6.6 per 100,000 individuals
annually in the USA, these malignancies result in a majority of deaths from
primary brain tumors. Historically, gliomas have been classified based on their
histological features and graded by their degree of anaplasia according to WHO
criteria, serving as a “gold standard” for decades. However, in the case of low
grade gliomas and particularly diffusely infiltrative gliomas, these methods
are subject to intra observer variability. Thus, with the advent of molecular
profiling, these tumors have now been further interrogated to identify
diagnostically relevant alterations, including genomic, transcriptomic, and
epigenetic variants, complementing the histological-based classification system
[3-5].
3.1.
IDH1 Mutation in
Glioma
The
recent identification of frequent mutations in the metabolic gene Isocitrate
Dehydrogenase (IDH) 1 and 2 suggests the existence of different molecular
subclasses of diffusely infiltrative gliomas with distinct biological and
clinical attributes, prompting the WHO to propose revised classification guidelines
[6]. Originally discovered in 2008 [7], it is now appreciated that 70-80% of grade II/III
and 20% grade IV gliomas harbor mutations in IDH1; and that these alterations
frequently coexist with TP53, ATRX mutations, and co-deletions of chromosome 1p
and 19q [8,9]. Prior studies have identified
mutations in IDH1 as one of the earliest events in gliomagenesis, possibly
playing a significant role during tumor initiation and subsequent transformation
[9-11]. The majority of IDH1 mutants contain heterozygous single amino acid missense mutation in
its active site at arginine 132, altering its enzymatic activity that
results in the neomorphic production of the
oncometabolite 2-Hydroxyglutarate (2-HG) using α-ketoglutarate
(α-KG) [12]. This
aberrant production of 2-HG in turn inhibits α-KG-dependent
dioxygenases, including histone demethylases and DNA demethylase Ten-Eleven
Translocation 2 (TET 2) [13-15].
Consequently, IDH mutation is associated with global changes in DNA and histone
methylation patterns as indicated by widespread hypermethylation of CpG islands [16]. Clinically, mutations in IDH1 prolong survival
of glioma patients [8]. Given the pronounced
frequency of IDH1 mutation in gliomas coupled with its impact on the biology
and clinical progression of the disease, it is vital to further delineate the
role of monoallelic IDH1 point mutations in gliomas.
3.2. Current Models for
Mutant IDH1
While previous studies have investigated the
biological function of mutant IDH1 in the context of tumorigenesis and tumor
progression, these studies are often limited by the paucity of appropriate endogenous
mutant IDH1 systems [17,18]. For instance, most prior studies have relied
on the use of overexpression systems, which do not necessarily recapitulate the
naturally occurring heterozygous IDH1 mutational status in this cancer [17]. Moreover, the underlying wild type IDH1 background in these
exogenously overexpressing IDH1 mutant clonal cells may obscure the true
biological and clinical impact of IDH1 mutation in this cancer. Although techniques
to establish primary cultures carrying monoallelic IDH1 mutants from human
tumor samples has been improved, it remains difficult to generate isogenic
cellular models to study the function of mutant IDH1, especially during
tumorigenesis [19]. Likewise, while orthotopic xenograft models
are available, their utility is often limited [20]. Thus, it is important to establish clinically relevant
cellular models that recapitulate the parental disease to methodically
characterize the role of IDH1 mutation in this cancer. Such clinically
representative in vitro disease models will enable systematic delineation of the
molecular network driven by mutated IDH1, a prerequisite for effective
therapeutic design.
3.3. An Efficient Approach
to Create Heterozygous IDH1 R132H Mutation
To this end, we recently demonstrated the use
of "Single base editing" method to generate isogenic cellular models carrying
monoallelic IDH1 mutants [21]. Using a
recently reported CRISPR-Cas9 technology which functions without the induction
of a double strand break in IDH1 [22], we precisely introduced heterozygous IDH1 R132H point
mutation in human astroglial cells with a successful rate of 20%. Compared with
other nuclease and homology directed
repair-based knock-in methods used to date [23-25], our
work provides an efficient
and easy approach to generate monoallelic IDH1
R132H mutation, and can be valuable to others in the
field searching for models of endogenous heterozygous IDH1 mutation.
The monoallelic IDH1 mutants in our model displayed
global alterations in DNA methylation and gene expression pattern coupled with
dramatic changes in cellular behavior including decreased cell proliferation. Notably,
we uncovered a previously unknown link between expression of YAP, an effector
of the pro-growth Hippo pathway, and IDH1 mutation status (Figure
1). Specifically, our work revealed a
Hippo-independent, 2-HG-dependent regulation of YAP expression in these
monoallelic IDH1 mutant astroglial clones. The Hippo-YAP pathway has emerged as
a critical network driving tumor growth and progression [26-28].
Thus, it is of interest to identify potent
regulators of YAP and their role in cancer development. Our study suggests that
YAP is responsive to changes in metabolic state, highlighting the intimate relationship
between proto-oncogenes and cellular metabolism. While further mechanistic
investigation is warranted to precisely elucidate the biological implication of
YAP inhibition by IDH1 mutation, this study lays the groundwork in establishing
a novel connection between oncometabolite production and activity of pro-growth
signaling network in early disease development. Overall, this versatile and
efficient “Single base gene editing” technique will permit thorough
interrogation of the biological function of heterozygous IDH1 mutants in the context
of glioma development and progression, and serve as a valuable model to test
effective therapies for the management and treatment of gliomas.
4.
Compliance
with Ethical Standards
4.1.
Funding: Dr. Xia
is supported by NIH R01NS091165. AQH was supported by the Mayo Clinic
Professorship and a Clinician Investigator award as well as the NIH (R43CA221490, R01CA200399, R01CA183827,
R01CA195503, R01CA216855).
4.2.
Conflict of
Interest:
The authors declare no conflict of interest.
4.3.
Ethical approval: This article does
not contain any studies with human participants or animals performed by any of
the authors.
Figure 1: Schematic of the mechanistic details and functional
effects of mutant IDH1-YAP signaling.